Sage Journals: Discover world-class research

Abstract

OBJECTIVE:

Since cancer treatment and outcome differ among the patients diagnosed with breast cancer at different stages, this study aims to elucidate the factors associated with PET/CT staging, treatment effect, and maximal standardized uptake value (SUV_max) in breast cancer patients.

METHODS:

Twenty-eight patients who underwent two PET/CT examinations with the complete pathological and immunohistochemical data were retrospectively reviewed. Pearson and Spearman correlation analyses were performed to investigate the relationships of patient PET/CT staging (first round PET/CT), treatment effect (comparison between the results of two rounds of PET/CT), and tumor SUV_max, with respect to patient age, tumor location, tumor long diameter, short diameter, time of first round PET/CT examination, histological type and grade, axillary lymph node metastasis rate, interval between the two PET/CT examinations, treatment method, and the expression of the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), P53, and Ki67.

RESULTS:

PET/CT staging (first round PET/CT) relates to HER2 and Ki67 expression with the correlation coefficients of 0.432 and 0.552, and P-values of 0.022 and 0.002, respectively. The treatment effect (comparison between the results of two rounds of PET/CT) associates with tumor site and P53 expression in which the correlation coefficients are – 0.412 and 0.845, and P-values are 0.029 and 0.000, respectively. The measured SUV_max correlates well with the tumor long diameter, short diameter, and treatment effect in which the correlation coefficients are 0.943, 0.886, and 0.878, and P-values are 0.005, 0.019, and 0.02, respectively.

CONCLUSIONS:

Study results indicate that PET/CT staging and treatment effect associate well with SUV_max and immunohistochemical results of tumor, while SUV_max of tumor associates well with tumor size.

Keywords

PET/CT FDG breast cancer

Get full access to this article

View all access options for this article.

References

Chen ,

Zheng ,

P.D.

Baade , et al. Cancer statistics in China, 2015, CA Cancer J Clin 66(2) (2016), 115–132.

Shin ,

Pak ,

D.Y.

Park , et al. Tumor heterogeneity assessed by ¹⁸F-FDG-PET/CT is not significantly associated with nodal metastasis in breast cancer patients, Oncol Res Treat 39(1-2) (2016), 61–66.

B.B.

Koolen ,

K.E.

Pengel ,

Wesseling , et al. Sequential (18) F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy, Eur J Nucl Med Mol Imaging 41(1) (2014), 32–40.

F.C.

Zhang ,

H.Y.

Xu ,

J.J.

Liu , et al. ¹⁸F-FDG-PET/CT for the early prediction of the response rate and survival of patients with recurrent or metastatic breast cancer, Oncol Lett 16(4) (2018), 4151–4158.

Senkus ,

Kyriakides ,

Ohno , et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol 26(Suppl 5) (2015), v8–v30.

M.E.

Hammond ,

D.F.

Hayes ,

A.C.

Wolff , et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Oncol Pract 6(4) (2010), 195–197.

Mannell , The role of Ki-67 in breast cancer, S Afr J Surg 54(2) (2016), 10–13.

Heusinger ,

S.M.

Jud ,

Haberle , et al., Association of mammographic density with hormone receptor in invasive breast cancers: Results from a case-only study, Int J Cancer 131(11) (2012), 2643–2649.

J.Q.

Shi ,

Y.S.

Wang and

Li , The epidemiological investigation of the menopause state and related factors in 50 years old women, Hebei Medical Journal 40(23) (2018), 3637–3640.

10.

Yararbas ,

N.C.

Avci ,

Yeniay , et al. The value of ¹⁸F-FDG-PET/CT imaging in breast cancer staging, Bosn J Basic Med Sci 18(1) (2018), 72–79.

11.

Fujii ,

Yajima ,

Kurozumi , et al. Clinical significance of 18F-FDG-PET in invasive lobular carcinoma, Anticancer Res 36(10) (2016), 5481–5485.

12.

Hong ,

Li and

Wang , ¹⁸F-FDG-PET/CT for diagnosis of distant metastases in breast cancer patients. A meta analysis, Sug Oncol 22(2) (2013), 139–143.

13.

E.A.

Mohamad Hanif and

S.A.

Shah , Overview on epigenetic re-programming: A potential therapeutic intervention in triple negative breast cancer, Asian Pac J Cancer Prev 19(12) (2018), 3341–3351.

14.

A.B.

Effi ,

N.A.

Aman ,

B.S.

Koui , et al. Breast cancer molecular subtypes defined by ER/PR and HER2 status: Association with clinicopathologic parameters in Ivorian patients, Asian Pac J Cancer Prev 17(4) (2016), 1973–1978.

15.

J.C.

Bloodgood , Cancer of the breast: Figures which show that education can increase the number of cures, JAMA 315(7) (2016), 709.

16.

H.M.

Asif ,

Sultana ,

Ahmed , et al. HER-2 positive breast cancer-a mini-review, Asian Pac J Cancer Prev 17(4) (2016), 1609–1615.

17.

W.H.

Talib ,

S.A.

Al-Hadid ,

M.B.W.

Ali , et al. Role of curcumin in regulating P53 in breast cancer: an overview of the mechanism of action, Breast Cancer 10(29) (2018), 207–217.

18.

B.S.

Kim and

S.H.

Sung , Usefulness of ¹⁸F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer, Ann Nucl Med 26(2) (2012), 175–183.

19.

Sanli ,

Kuyumcu ,

Z.G.

Ozkan , et al. Increased FDG uptake in breast cancer is associated with prognostic factors, Ann Nucl Med 26(4) (2012), 345–350.

20.

Groheux ,

Cochet ,

Humbert , et al. ¹⁸F-FDG-PET/CT for staging and restaging of breast cancer, J Nucl Med 57(Suppl 1) (2016), 17S–26S.

Correlation analysis of 18 F-FDG PET/CT for the staging and treatment effect assessment of breast cancer